Publications by authors named "H Lindemann"
The multicenter, phase III GMMG ReLApsE trial (EudraCT-No:2009-013856-61) randomized relapsed and/or refractory multiple myeloma (RRMM) patients equally to lenalidomide/dexamethasone (LEN/DEX, 25mg days 1-21/40mg weekly, 4-week cycles) re-induction, salvage high dose chemotherapy (sHDCT, melphalan 200mg/m2), autologous stem cell transplantation (ASCT) and LEN maintenance (10mg/day; transplant arm, n=139) versus continuous LEN/DEX (control arm, n=138). Ninety-four percent of patients had received frontline HDCT/ASCT. We report an updated analysis of survival endpoints with a median follow-up of 99 months.
View Article and Find Full Text PDFArticle Synopsis
- Porphyrias are genetic metabolic disorders that disrupt enzymes involved in producing porphyrin and heme, leading to toxic byproducts like porphyrins.
- Symptoms vary widely, including skin issues in sunlight and dangerous neurovisceral attacks.
- Diagnosis involves biochemical tests of urine, blood, and stool, and treatment is complex, often needing collaboration among various medical specialists.
Hydroalcoholic Extract of Centella asiatica and Madecassic Acid Reverse Depressive-Like Behaviors, Inflammation and Oxidative Stress in Adult Rats Submitted to Stress in Early Life.
Mol Neurobiol
December 2024
Article Synopsis
- Major depressive disorder (MDD) significantly impacts quality of life, particularly linked to stress from maternal deprivation (MD), and traditional treatments often have serious side effects.
- Centella asiatica (C. asiatica) and its compound madecassic acid show promise for alleviating depressive-like behaviors and reducing inflammation and oxidative stress in young rats subjected to MD.
- The study demonstrated that treatment with C. asiatica extracts led to improvements in behavior, decreased inflammatory markers, and reduced oxidative stress in the brain and serum, suggesting their potential as antidepressant agents.
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
Ann Hematol
July 2024
Rituximab, gemcitabine and oxaliplatin (R-GemOx) has demonstrated to be effective and safe in lymphoma patients. We aimed to determine the maximum tolerated dose (MTD) of oxaliplatin in combination with rituximab and gemcitabine and to explore the efficacy and safety of R-GemOx in relapsed or refractory (r/r) indolent and mantle cell lymphoma (MCL). In this single-arm, phase I/II trial, we enrolled 55 patients with r/r indolent lymphoma and MCL not suitable for autologous stem-cell transplantation.
View Article and Find Full Text PDFObjectives: The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains unknown.
Methods: Here, we analyzed the CMV immunoglobulin (Ig) serology of 446 newly-diagnosed multiple myeloma (MM) patients of the GMMG-MM5 phase III trial with a median follow-up of 58 months.